bubble image


Rapidly advancing a robust pipeline of novel immuno-dermatology drug candidates targeting multiple dermatologic indications


Arcutis’ pipeline includes best-in-class molecules that are the products of scientific advances in the understanding of key immunology targets, such as phosphodiesterase-4 (PDE4) and Janus kinase one (JAK1), and their role in the inflammation that drives many dermatological conditions. Our unique formulation expertise enables us to develop proprietary topical formulations that are optimized for dermatological applications, even for molecules that present specific challenges.

The four novel products within Arcutis’ pipeline address large segments of the dermatology market and include topical roflumilast cream (ARQ-151) for plaque psoriasis and atopic dermatitis; topical roflumilast foam (ARQ-154) for seborrheic dermatitis and scalp psoriasis; ARQ-252 cream (JAK 1 inhibitor) for hand eczema and vitiligo; and ARQ-255, an alternative topical formulation of ARQ-252 for alopecia areata.